Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text

Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

Journal of the American Academy of Dermatology
Volume 62, n° 3
pages 516-517 (mars 2010)
Doi : 10.1016/j.jaad.2009.06.003
Research Letters

Goeckerman therapy versus biologics in the treatment of psoriasis

Alan Menter, MD
Baylor Research Institute, Dallas, Texas 

Correspondence to: Alan Menter, MD, Baylor Research Institute, 3900 Junius St, Suite 145, Dallas, TX 75246.

 Funding sources: None.
 Disclosure: Dr Menter is an advisory board member, consultant, investigator, and speaker receiving grants and/or honoraria from Abbott, Amgen, Astellas, Centocor, Genentech, Warner Chilcott, and Wyeth. He is a consultant and investigator receiving grants from Eli Lilly; and advisory board member, consultant and speaker receiving honoraria from Galderma; and an investigator receiving grants from Novartis and Novo Nordisk.

Top of the page

© 2009  American Academy of Dermatology, Inc.@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Article Outline
You can move this window by clicking on the headline